-
Thermo Fisher’s lab in Gothenburg opens
Thermo Fisher’s clinical research business, PPD, is opening its first bioanalytical laboratory in Europe. The company chose Gothenburg for the new facility, which is now operational and expected to create 140 jobs.
-
Positive outcome in phase III for Sanofi’s eczema treatment
The antibody amlitelimab shows positive Phase III data as a treatment for atopic dermatitis. France‑based Sanofi now plans to submit global regulatory applications before the end of the year.
-
Gothenburg-based Anyo Labs gains ground in the AI race
In a fifty-square-metre space in Gothenburg sits a company aiming to secure its place on one of the world's hottest technological stages: AI-driven drug development. “We are driven by the technical challenge and by ensuring that we have the best possible tools,” the company’s CEO tells Life Science Sweden during our visit.
-
“There’s no magic wand” – The urgent need for new treatments
One in ten women with recurrent yeast infections develops a stubborn, hard-to-treat condition for which no effective therapies currently exist. At Danderyd Hospital, researcher Cathrin Alvendal at the Women’s Clinic research unit is working to change that. This is the second instalment in Life Science Sweden’s series on fungi.
-
Pfizer vinner budstriden om fetmauppstickaren Metsera
Pfizer har slutit ett avtal på 10 miljarder dollar, motsvarande 95 miljarder kronor, för att köpa det amerikanska bioteknikbolaget Metsera, efter att Novo Nordisk meddelat att de drar sig ur den intensiva budstriden.
-
Läkemedelsjättar i bitter strid om fetmauppstickare
Ett budkrig har brutit ut inom fetmabehandlingar, där Pfizer och Novo Nordisk slåss med näbbar, klor och miljardbelopp om att få köpa det nystartade läkemedelsbolaget Metsera.
-
Phase III win for Hansa Biopharma: “We Are Thrilled”
Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.
-
Pfizer jagar fotfäste på obesitasmarknaden – förvärvar Metsera
Pfizer förvärvar amerikanska viktminskningsbolaget Metsera. Affären är initialt värd 4,9 miljarder dollar, motsvarande cirka 46 miljarder kronor, men kan stiga om vissa kliniska och regulatoriska mål uppnås
-
Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm
One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.
-
FDA plans to replace animal testing with AI – “Paradigm shift”
The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met with skepticism from the National Association for Biomedical Research.
-
Aqilion's licensing journey: From Merck partnership to new opportunities
Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO Sarah Fredriksson and is directed at biotech companies aiming to find a good licensing partner.
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
Health politician Lina Nordquist: ”I find it hard to be idle”
She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decided to make a change from within. Life Science Sweden meets Lina Nordquist, Member of Parliament for the Liberals and their spokesperson on healthcare policy, to have a conversation about reality, politics, and the need for writing.
-
Norwegian cancer research companies merge
The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.
-
This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”
This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understanding the mechanism has changed our view of human biology and evolution, says KI Professor András Simon.
-
“We should avoid surgery if we can”
Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about role models, surgery and Sweden’s strengths and weaknesses in medical research.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be respected, to not have their identity overshadowed by their condition”, writes Anna Törner in a column.
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other industries for inspiration and knowledge.
-
Life science-staden Göteborg – Vi är ”Lilla Boston”
I Västsverige satsar man på life science inom alltifrån avancerade terapiläkemedel till femtech. Samtidigt blickar aktörerna mot andra branscher för inspiration och kunskap.
-
”Att forska vid universitet blir alltmer som att verka vid ett forskarhotell”
Regeringen vill att svensk forskning ska fokusera på excellens och innovation. Men går det att kombinera de två? Life Science Sweden samtalar med Anna Falk, professor i Lund, om forskningspolitik, om den ständiga jakten på anslag inom akademin och om vad som egentligen är ”finforskning”.
-
Framtida forskningsanläggningen ESS ska ge forskarna nya insikter på atomnivå
ESS i Lund ska bli ett viktigt verktyg för materialforskare i framtiden. Vi besöker anläggningen för att se hur långt de kommit.
-
Nocebo – the evil twin that makes you feel worse
The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala researcher Charlotte Blease, co-author of a book on the phenomenon.
-
Anna Törner: ”Mitt kvantifierade liv”
”Uttrycket om att man inte ser skogen för alla träd känns nyaktuellt i kontexten wearbales. Det är lätt att fångas av tanken att ju mer vi mäter, desto mer vet vi”, skriver Anna Törner i en krönika.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic have achieved just that, and they are thus making a significant contribution to the history of Swedish medicine. He is now being awarded the Research!Sweden Award 2023.
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Redan prenumerant? Logga in
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
Annons
Annons
Annons
Annons
BREAKING